In this issue:
TMB for identifying survival and antitumour immunity in microsatellite stable disease
Ipilimumab/nivolumab for metastases with homologous recombination deficiency pathogenic germline variants
Neoantigen T-cell receptor gene therapy for pancreatic cancer
First-line FOLFIRINOX vs. gemcitabine + nab-paclitaxel for metastatic PDAC
Panitumumab, chemotherapy, and external-beam RT for locally advanced PDAC
G-CSF and chemotherapy dose-intensity, and link between dose-intensity and survival, in metastatic PDAC
Total neoadjuvant therapy for PDAC increases pathological CR
Predicting local tumour control and RFS in resected PDAC after neoadjuvant chemoradiotherapy
COVID-19 pandemic has led to reduced survival after PDAC diagnosis
Impact of COVID-19 pandemic on the management of metastatic PDAC
Please login below to download this issue (PDF)